| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 25059 |
| Drug | Vorasidenib |
| Brand | Voranigo® |
| Indication | Vorasidenib (Voranigo®) is indicated as monotherapy for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 01/10/2025 |
| Rapid review completed | 23/10/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of vorasidenib compared with the current standard of care. |
| Full HTA commissioned by the HSE | 29/10/2025 |
| Pre-submission consultation with Applicant | 09/12/2025 |
| Full submission received from Applicant | 05/05/2026 |
| Preliminary review sent to Applicant | 20/07/2026 |
| NCPE assessment re-commenced | 14/08/2026 |
| Factual accuracy sent to Applicant | 17/09/2026 |
| NCPE assessment re-commenced | 24/09/2026 |
| NCPE assessment completed | 13/10/2026 |
| NCPE assessment outcome | The NCPE recommends that vorasidenib (Voranigo®) be considered for reimbursement, for this indication, if cost-effectiveness can be improved relative to existing treatment*. |
*Next steps: The NCPE Assessment Report and recommendation and Patient Organisation submission, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health Pricing and Supply of Medical Goods Act 2013.
Further information on this process may be found here.
Please see the HSE Pricing and Reimbursement Tracker for any updates on the reimbursement status of this drug.
HSE Pricing and Reimbursement Tracker